17,261 trials
Cancer
Primary: Overall Response Rate (ORR) — 27; 39; 23; 4 Participants
Prolymphocytic Leukemia · Recurrent Adult Hodgkin Lymphoma · Recurrent Childhood Hodgkin Lymphoma
Primary: Engraftment of HLA Identical PBSC Allografts — 53 Participants
Meningococcal Disease
Primary: Percentages of Subjects Without Bactericidal Activity at 1:4 Dilution Against Each US Neisseria Meningitides (N. Meningitidis) Serogroup B Strain at 1 Month After the…
Infection, Human Immunodeficiency Virus
Primary: Change From Baseline in Plasma Human Immunodeficiency Virus (HIV-1) Ribonucleic Acid (RNA) to Day 11 — -2.169; -0.092 log10 copies/mL — p=<0.001
Autoimmune Pancytopenia · Autoimmune Lymphoproliferative Syndrome (ALPS) · Evans Syndrome
Primary: Number of Participants With Grade 3 and 4 Toxicities of Administration of Oral Sirolimus — 1 participants
Tobacco Use Disorder
Primary: Product Effect on Complete Substitution for Smoking — 56; 56 participants
Diabetes Mellitus, Type 2
Primary: Change From Baseline (Week 0) in Glycosylated Hemoglobin (HbA1c) (%) at Week 12 — -0.31; -1.04; -0.96; -1.05 Percentage of hemoglobin — p=<0.001
Adenocarcinoma of the Prostate · Hormone-resistant Prostate Cancer · Recurrent Prostate Cancer
Primary: Phase I: Frequency of Dose Limiting Toxicities of Alisertib, Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)…
Plaque-type Psoriasis
Primary: Number of Participants With Adverse Events, Serious Adverse Events and Deaths — 44; 41; 180; 9 Participants
Endometrial Adenocarcinoma · Endometrial Adenosquamous Carcinoma · Endometrial Clear Cell Adenocarcinoma
Primary: Proportion of Patients With Objective Tumor Response Rate (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.0 — 1; 0 Participants
Lymphoma
Primary: Complete Response Rate — 23 percentage of participants
Macular Degeneration
Primary: Change From Baseline (Day 1) in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Over Period — 3.5; -0.4; 1.1; 1.8 Millimeters of mercury (mmHg)
Hypercholesterolemia
Primary: Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12 — -2.6; -36.9; -47.6; -56.0 milligram per deciliter (mg/dL) — p=<0.001
Arthritis, Rheumatoid
Primary: Percentage of Participants With an American College of Rheumatology (ACR) 50 Response at Week 12 (Part B) — 3.3; 26.7; 23.3; 26.7 Percentage of Participants — p=0.026
Prostate Cancer · Prostatic Neoplasms
Primary: Percentage of Patients Free of Progression and Without Symptomatic Deterioration — 24; 9 percentage of Participants